IL202519A0 - 1-cyanocyclopropyl derivatives as cathepsin k inhibitors - Google Patents

1-cyanocyclopropyl derivatives as cathepsin k inhibitors

Info

Publication number
IL202519A0
IL202519A0 IL202519A IL20251909A IL202519A0 IL 202519 A0 IL202519 A0 IL 202519A0 IL 202519 A IL202519 A IL 202519A IL 20251909 A IL20251909 A IL 20251909A IL 202519 A0 IL202519 A0 IL 202519A0
Authority
IL
Israel
Prior art keywords
cyanocyclopropyl
cathepsin
inhibitors
derivatives
cyanocyclopropyl derivatives
Prior art date
Application number
IL202519A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Heron Nicola Murdoch
Dossetter Alexander Graham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Heron Nicola Murdoch, Dossetter Alexander Graham filed Critical Astrazeneca Ab
Publication of IL202519A0 publication Critical patent/IL202519A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL202519A 2007-06-26 2009-12-03 1-cyanocyclopropyl derivatives as cathepsin k inhibitors IL202519A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94617807P 2007-06-26 2007-06-26
US4284008P 2008-04-07 2008-04-07
PCT/GB2008/050486 WO2009001129A1 (en) 2007-06-26 2008-06-24 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors

Publications (1)

Publication Number Publication Date
IL202519A0 true IL202519A0 (en) 2010-06-30

Family

ID=39761131

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202519A IL202519A0 (en) 2007-06-26 2009-12-03 1-cyanocyclopropyl derivatives as cathepsin k inhibitors

Country Status (19)

Country Link
US (1) US8008279B2 (enExample)
EP (1) EP2170879B1 (enExample)
JP (1) JP2010531344A (enExample)
KR (1) KR20100039862A (enExample)
CN (1) CN101687864A (enExample)
AR (1) AR067156A1 (enExample)
AU (1) AU2008269513B2 (enExample)
BR (1) BRPI0813306A2 (enExample)
CA (1) CA2689945A1 (enExample)
CL (1) CL2008001899A1 (enExample)
CO (1) CO6251264A2 (enExample)
EC (1) ECSP109882A (enExample)
IL (1) IL202519A0 (enExample)
NZ (1) NZ581719A (enExample)
PE (1) PE20090841A1 (enExample)
RU (1) RU2470023C2 (enExample)
TW (1) TW200911806A (enExample)
UY (1) UY31180A1 (enExample)
WO (1) WO2009001129A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP5666036B2 (ja) * 2008-01-25 2015-02-04 メディベイション テクノロジーズ， インコーポレイテッド 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
CN102227431A (zh) 2008-09-29 2011-10-26 雅培制药有限公司 吲哚和二氢吲哚衍生物及其应用方法
AU2009336040B2 (en) * 2008-12-18 2015-07-16 Merck Patent Gmbh Tricyclic azaindoles
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
CN102666526A (zh) 2009-10-21 2012-09-12 贝林格尔.英格海姆国际有限公司 作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
CN104592233A (zh) 2009-12-17 2015-05-06 Abbvie公司 用于治疗神经变性和神经精神紊乱的桥头胺环稠合吲哚和二氢吲哚
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8815843B2 (en) 2011-02-18 2014-08-26 Medivation Technologies, Inc. Compounds and methods of treating diabetes
JP6068505B2 (ja) * 2012-01-11 2017-01-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ プロテアーゼ阻害剤としてのマクロ環式アミド
CN103086923B (zh) * 2013-01-21 2014-04-23 吉林大学 肼腈类组织蛋白酶k抑制剂及其在治疗骨质疏松症方面的应用
JP6454335B2 (ja) * 2013-10-08 2019-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． カテプシンシステインプロテアーゼ阻害剤
WO2016027285A2 (en) * 2014-08-22 2016-02-25 Alkem Laboratories Ltd. Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
CN105837479B (zh) * 2016-04-05 2017-10-27 吉林大学 肼腈类组织蛋白酶k抑制剂及其在制备治疗骨关节炎药物中的应用
IL302144A (en) * 2017-03-29 2023-06-01 Minerva Biotechnologies Corp Agents for stem cell differentiation and cancer treatment
WO2023138695A1 (zh) * 2022-01-21 2023-07-27 山东新时代药业有限公司 一种组织蛋白酶k抑制剂与其制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2379747C (en) * 1999-07-30 2008-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
AU779855B2 (en) * 2000-01-06 2005-02-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
JP4365094B2 (ja) * 2001-03-02 2009-11-18 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
RU2004120784A (ru) * 2001-12-04 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Замещенные 2-аминоциклоалканкарбоксамиды и их применение в качестве ингибиторов цистеиновой протеазы
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
PL377426A1 (pl) 2002-12-19 2006-02-06 Bristol-Myers Squibb Company Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego

Also Published As

Publication number Publication date
UY31180A1 (es) 2009-01-30
TW200911806A (en) 2009-03-16
RU2470023C2 (ru) 2012-12-20
AU2008269513B2 (en) 2011-06-16
PE20090841A1 (es) 2009-08-02
US8008279B2 (en) 2011-08-30
CA2689945A1 (en) 2008-12-31
JP2010531344A (ja) 2010-09-24
CO6251264A2 (es) 2011-02-21
BRPI0813306A2 (pt) 2017-05-16
WO2009001129A9 (en) 2010-02-04
US20090012077A1 (en) 2009-01-08
WO2009001129A1 (en) 2008-12-31
CN101687864A (zh) 2010-03-31
NZ581719A (en) 2011-08-26
KR20100039862A (ko) 2010-04-16
CL2008001899A1 (es) 2009-07-17
RU2010101279A (ru) 2011-08-10
AU2008269513A1 (en) 2008-12-31
ECSP109882A (es) 2010-02-26
EP2170879B1 (en) 2013-01-16
AR067156A1 (es) 2009-09-30
EP2170879A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
IL202519A0 (en) 1-cyanocyclopropyl derivatives as cathepsin k inhibitors
DK2421826T3 (en) Proline derivatives as cathepsin inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA200809800B (en) 2-Thioxanthine derivatives acting as Mpo-inhibitors
PL2078001T3 (pl) Pochodne diazepano-acetamidowe jako selektywne inhibitory 11-hsd1
IL213694A (en) Melanin suppressant compounds
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
EP2237793A4 (en) INHIBITORS OF CATHEPSIN B
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200905761B (en) Transpiration inhibitor
ZA201200811B (en) Cathepsin c inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200908633B (en) 1-Cyanocyclopropyl-Derivatives as cathepsin K inhibitors
EP2076490A4 (en) INHIBITORS OF CATHEPSIN B
HK1142902A (en) 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors
GB0720364D0 (en) Inhibitor
GB0707632D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors